Experts Warn U.S. Funding Cuts Threaten AI Drug Discovery Leadership

Industry leaders at Fortune’s Brainstorm Tech conference have issued a stark warning regarding the U.S. government’s recent decision to reduce national health funding. As the biotech sector enters a pivotal era of AI-driven innovation, experts argue that cutting resources now creates a significant sovereign disadvantage. With international competitors in Europe and Asia aggressively increasing their investments in AI-integrated life sciences, the U.S. risks losing its competitive edge in a field that is fundamentally reshaping the scientific method.

AI drug discovery is currently a $3.25 billion market, with projections suggesting it will exceed $10 billion by 2031. The technology is moving beyond simple data processing; companies like Lila Sciences are utilizing 'agentic' AI—systems capable of performing the scientific method autonomously—to discover high-performing catalysts and molecules that human researchers might overlook. This shift represents a 'ChatGPT moment' for science, where AI systems can operate around the clock to accelerate breakthroughs in chemistry and biology.

Despite the influx of private capital, such as the $2.1 billion raised by Isomorphic Labs, industry leaders emphasize that government support remains essential for foundational research and the development of open-source models. NVIDIA’s Kimberly Powell highlighted that relying solely on closed, proprietary models could stifle the broader ecosystem. Furthermore, the industry faces regulatory hurdles, specifically regarding how the FDA will eventually validate AI-designed molecules. While experts remain optimistic that 'digital twin' models of biology will eventually satisfy regulatory requirements, the path forward requires sustained, long-term investment to ensure the U.S. remains at the forefront of this scientific revolution.